At MorphoSys, our mission is to make exceptional, innovative biopharmaceuticals to improve patients’ lives. Based on our leadership in generating antibodies we, with our partners, have developed >100 product candidates - 29 in clinical development and one on the market. Tafasitamab, our most advanced proprietary product candidate, is in late stage clinical development for the treatment of relapsed/refractory DLBCL patients. MorphoSys US Inc., Boston, is a fully owned subsidiary of MorphoSys AG.